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ABSTRACT
Objective: The prevalence of type 2 diabetes, often leading to
diabetic nephropathy, has increased globally, especially in
Asia. Irbesartan treatment delays the progression of kidney
disease at the early (microalbuminuria) and late (proteinuria)
stages of nephropathy in hypertensive type 2 diabetics. This
treatment has proven to be cost-effective in Western coun-
tries. This study assessed the cost-effectiveness of early irbe-
sartan treatment in Asian settings.
Methods: An existing lifetime model was reprogrammed in
Microsoft Excel to compare irbesartan started at an early
stage to irbesartan or amlodipine started at a late stage, and
standard treatments from a health-care perspective in China,
Malaysia, Thailand, South Korea, and Taiwan. The main
effectiveness parameters were incidences of end-stage renal
disease, time in dialysis, and life expectancy. All costs were
converted to 2004 US$ using ofﬁcial purchasing power
parity. Local data were obtained for costs, transplantation,
dialysis, and mortality rates. Probabilities regarding disease
progression after treatment with the investigated drugs were
extracted from two published clinical trials. A probabilistic
sensitivity analysis was performed.
Results: Early use of irbesartan yielded the largest clinical
and economic beneﬁts reducing need for dialysis by 61%
to 63% versus the standard treatment, total costs by 9%
(Thailand) to 42% (Taiwan), and increasing life expectancy
by 0.31 to 0.48 years. Early irbesartan had a 66% (Thailand)
to 95% (Taiwan) probability of being dominant over late
irbesartan.
Conclusion: Although the absolute results varied in different
settings, reﬂecting differences in epidemiology, management,
and costs, early irbesartan treatment was a cost-effective
alternative in the Asian settings.
Keywords: amlodipine; cost-effectiveness; hypertension; irbe-
sartan; nephropathy; type 2 diabetes.
Introduction
The World Health Organization (WHO) has high-
lighted the rapidly growing burden of diabetes world-
wide. Globally, an estimated 30 million people were
diagnosed with diabetes in 1985; this value increased
to 135 million in 1995, and in the year 2000, it
reached 177 million. More importantly, diabetes is
expected to affect more than 300 million people by
2025 [1]. This epidemic can be attributed to demo-
graphic aging and changes in lifestyle (e.g., globaliza-
tion, rural-to-urban shifts, and changes in diet and
physical activity). In the West, awareness regarding
this phenomenon is widespread. Nevertheless, al-
though Asia is also dramatically affected by diabetes,
the awareness levels remain relatively low [1–3]. In
Malaysia, for instance, the overall prevalence of dia-
betes (types 1 and 2) drastically increased from 0.65%
in 1960 to approximately 8% to 12% in the mid-
1990s; moreover, a 1998 study conducted in rural and
semiurban Malaysia revealed that the prevalence
was 14.0%, ranging between 7.1% and 20.3% [4]. In
China, diabetes prevalence increased from 1.0% in
1979 to 3.21% in 1996 [5]. By 2025, China will have
the highest number of diabetics worldwide, second
only to India [1,3].
Diabetic nephropathy is a common and serious
complication of diabetes [6]. Among patients starting
dialysis in Malaysia, diabetic nephropathy was found
to be the responsible cause in 51.7% of all end-stage
renal disease (ESRD) cases [7]. Therefore, with the
increasing prevalence of diabetes, the incidence of
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ESRD is also expected to increase in Asian regions.
This correlates well with the fact that Malaysia already
has one of the highest diabetic dialysis rates in the
world [8].
Several trials have established the renoprotective
effects of angiotensin receptor blockers (ARBs) on the
progression of renal disease in patients with hyper-
tension and type 2 diabetes [9–11]. Two prospective
clinical trials—the Irbesartan in Reduction of
Microalbuminuria-2 (IRMA-2) study [12] and the
Irbesartan in Diabetic Nephropathy Trial (IDNT)
[13]—speciﬁcally investigated the effect of irbesartan,
an ARB, on type 2 diabetic hypertensive patients with
microalbuminuria (MAU) (early diabetic nephropa-
thy) and proteinuria (late diabetic nephropathy),
respectively.
The results of these two trials were utilized as
primary data to investigate the clinical and economic
impact of different therapeutic strategies for patients
with type 2 diabetes, hypertension, and nephropathy
(e.g., early irbesartan treatment versus late irbesartan
treatment) through a Markov model. In the United
States, France, United Kingdom, Hungary, Italy, Spain,
and Germany, this model established the cost-
effectiveness (i.e., greater improvements in projected
life expectancy and lowest overall costs) of initiating
irbesartan treatment in type 2 diabetics with MAU as
compared to initiating either irbesartan or amlodipine
treatment in type 2 diabetics with proteinuria or
treating patients with standard therapies (i.e., antihy-
pertensive therapy that excludes drugs affecting
the renin-angiotensin system and dihydropyridine
calcium-channel blockers) [14–18].
These conclusions can, however, be challenged
when adapting the Markov model to different health-
care settings because of the variability of certain
factors such as epidemiology, disease evolution, treat-
ment patterns, and the associated cost.
Therefore, the objective of this work was to assess
the health and economic effects of the initiation of
early irbesartan treatment compared either to late irbe-
sartan or amlodipine treatment or to standard thera-
pies in ﬁve Asian settings (China, Malaysia, South
Korea, Taiwan, and Thailand) by adapting the existing
Markov model to each speciﬁc setting.
Methods
Model Description
The model used in this analysis explores long-term
costs from a third-party payers’ perspective and the
health consequences for patients with type 2 diabetes,
hypertension, and MAU through the following seven
stages on a 25-year time horizon (Fig. 1) [14–18].
• MAU (24-hour urinary albumin excretion
[(UAE]), 20–199 mg/minute);
• Early diabetic nephropathy (UAE ranging from
200 mg/minute to a median value of 1900 mg/
24 hours);
• Advanced diabetic nephropathy (median UAE on
admission, 1900 mg/24 hours);
• Doubling of serum creatinine (DSC);
• ESRD treated by dialysis;
• ESRD treated by renal transplant;
• Death.
Death
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Figure 1 Model structure. BP, blood pressure; DSC, doubling of serum creatinine; IDNT, Irbesartan in Diabetic Nephropathy Trial; IRMA-2, Irbesartan in
Reduction of Microalbuminuria-2; MAU, microalbuminuria.
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This model simulates a hypothetical cohort of 59-year-
old patients with type 2 diabetes, hypertension, and
MAU (UAE = 20–199 mg/minute on two of three con-
secutive occasions), presenting characteristics similar
to that of the baseline population in the IRMA-2 study
[12] (see Table 1), and following one of the following
four treatment strategies:
Standard treatment. Standard antihypertensive
therapy alone, excluding the use of acetylcholine
esterase (ACE) inhibitors, ARBs, and dihydropyridine
calcium-channel blockers.
Early irbesartan treatment. Standard antihypertensive
therapy plus administration of 300 mg/day irbesartan
at the onset of MAU.
Late irbesartan treatment. Standard antihypertensive
therapy plus administration of 300 mg/day irbesartan
once the patients reach the advanced diabetic nephr-
opathy stage.
Late amlodipine treatment. Standard antihypertensive
therapy plus administration of 10 mg/day amlodipine
once the patients reach the advanced diabetic nephr-
opathy stage.
Given the age of the patients at entry of the model,
the 25-year time horizon was to be approximating a
lifetime horizon. This seminal model [14–18] was
reprogrammed in Microsoft Excel 2003® (Microsoft,
USA) format to facilitate adaptations to ﬁve different
Asian settings, namely, China, Thailand, Taiwan,
South Korea, and Malaysia, while also increasing
transparency for the model user.
Transition Probabilities
The transition probabilities between the health states
of disease progression (from MAU to ESRD) were
those used in the adaptations of the seminal model
[14–18]. These reﬂected the disease progression
as reported in the IRMA-2 study and the IDNT
for a patient under each speciﬁc treatment investi-
gated. These transition probabilities, presented in
Table 2, were assumed to apply to the Asian setting
investigated.
In the case of advanced nephropathic stages (i.e.,
ESRD), the treatment pattern was assumed, after vali-
dation with local experts in each settings, to be iden-
tical regardless of the initial treatment strategies and
was established based on the probabilities of dialysis,
transplantation, and death in each stage. Since ESRD
management differed across regional health-care
settings, the transition probabilities for these stages
(i.e., transplantation probability and dialysis) were
obtained for each setting from available local data (i.e.,
peer-reviewed articles, expert opinions, national regis-
tries, chart reviews, and/or national statistics) (see
Table 3 for the data sources used in each setting and
Table 4 for transition probabilities speciﬁc to each
setting).
Themortality rates for patientswithMAU, early and
advanced diabetic nephropathy, and DSC were setting
and age-dependent. These were calculated by adjusting
the age- and sex-speciﬁc all-cause mortality values that
were published by the WHO for Malaysia, China,
South Korea, and Thailand [19] or by using the ofﬁcial
statistics [20] for Taiwan, by health state-dependent
relative risks (RRs) reported in the seminal model
[14–18]. The MAU and overt nephropathy RR were,
respectively, valued at 2.03 and 4.4. These were deter-
mined, based on Danish data, by comparing mortality
Table 1 Baseline characteristics of patients in the IRMA-2 study (adapted from [10])
Standard blood pressure
control (n = 201)
Irbesartan, 300 mg
(n = 194)
Demographic characteristics
Age (year) 58.3 8.7 57.3 7.9
Male (%) 68.7 70.6
Clinical characteristics
Body-mass index (kg/m2) 30.3 4.4 30.0 4.3
Known duration of diabetes (year) 10.4 8.6 9.2 6.9
Any type of retinopathy (%) 44.6 35.8
Nonsmokers (%) 47.8 41.2
Laboratory variables
Blood pressure (systolic) (mmHg) 153 15 153 14
Glycosylated hemoglobin (%) 7.1 1.6 7.1 1.7
Urinary albumin excretion (mg/minute) 54.8 2.5 53.4 2.2
Serum creatinine (mg/dL)
Male patients 1.1 0.1 1.1 0.2
Female patients 0.9 0.1 1.0 0.2
Triglycerides (mmol/l) 1.9 1.2 2.1 1.3
Total cholesterol (mmol/l) 5.8 1.1 5.8 1.2
IRMA-2, Irbesartan in Reduction of Microalbuminuria-2.
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rates in speciﬁc health states to mortality among the
general population [21,22]. Because of the absence of
data for the DSC state, the RR of overt nephropathy
was conservatory used. For the sex adjustment the
68.7% male proportion observed in the IRMA-2 study
was used.
Costs Included in the Model
Costs were expressed in 2004 US$ after conversion of
setting speciﬁc cost data using the health-care product
price index for update to 2004 values, and ofﬁcial
purchasing power parity for conversion from local
currency to US$ [23,24]. Cost data were retrieved from
different sources depending on local availability (pub-
lished data in China and Malaysia; insurance or hospi-
tal databases in Taiwan, Thailand, and South Korea)
(see Table 2). The costs of concomitant medication,
including all other antihypertensive agents, were
assumed to be similar between treatment regimens and
were excluded from the cost calculation. The speciﬁc
costs in each Asian setting are presented in Table 5.
Effectiveness Parameters
The model investigated the impact of the four treat-
ment options on the cumulative incidence of ESRD,
the number of years the patients lived free of ESRD,
the number of days in dialysis, and the number of
life-years saved.
Discount Rate
An annual discount rate of 3% was applied for both
future costs and outcomes. This corresponds to the
discount rate that is generally recommended for health
economic evaluations [25,26] and applied in health
economic studies performed from an Asian perspective
[27–30].
Sensitivity Analysis
Sensitivity analysis was conducted using two comple-
mentary approaches: deterministic and probabilistic
sensitivity analyses. One-way deterministic sensitivity
analysis was performed to individually assess the sen-
sitivity of both cost and outcomes calculated by the
model to the uncertainty around each key input
parameter and to determine which speciﬁc parameter
had the largest effect on the results after assigning
extreme values (deﬁned as 50% of the values
obtained in the base-case analysis) to key input
parameters (drug costs, transplantation probability,
mortality, and RRs). The time horizon was also
included in this analysis in the form of a threshold
analysis and by assessing overall cost after varying
the time horizon from 0 to 30 years. The probabilis-
tic sensitivity analysis (second-order Monte Carlo
simulation) was used to assess the effect of uncer-
tainty around the model results given uncertainty
around each input parameter. From this analysis,
95% conﬁdence intervals round the overall costs and
health outcomes investigated in the model were pro-
duced [26] and the probability that the incremental
cost-effectiveness ratio (ICER) of a given treatment
would be below a threshold ICER (cost-effectiveness
acceptability) was determined.
Table 2 Transition probabilities, determined from the IRMA-2 and IDNT study, applied to all Asian settings
Irbesartan
(300 mg daily)
Standard blood
pressure control alone
Amlodipine
(10 mg daily)
Progression from MAU to early diabetic nephropathy
Year 1 0.025 0.095 NA
Years 2+ 0.036 0.083 NA
Progression from early diabetic nephropathy to advanced
diabetic nephropathy
Year 0 0.068
Year 1 0.455
Year 2 0.367
Year 3 0.526
Year 4 0.667
Year 5 0.667
Year 6 0
Year 7 0
Years 8+ 1
Progression from advanced diabetic nephropathy to DSC
Year 1 0.007 0.014 0.014
Year 2 0.045 0.049 0.051
Year 3 0.042 0.064 0.087
Years 4+ 0.032 0.042 0.051
Progression from advanced diabetic nephropathy to ESRD
Year 1 0.031 0.025 0.027
Year 2 0.021 0.045 0.048
Year 3 0.025 0.04 0.041
Years 4+ 0.026 0.036 0.038
Progression from DSC to ESRD
Years 1+ 0.538 0.604 0.56
DSC, doubling of serum creatinine; ESRD, end-stage renal disease; IDNT, Irbesartan in Diabetic Nephropathy Trial; IRMA-2, Irbesartan in Reduction of Microalbuminuria-2; MAU,
microalbuminuria; NA, not available.
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To perform this probabilistic analysis, a speciﬁc
distribution was attributed to each parameter around
the point estimate used in the principal analysis. A
triangular distribution, ranging from -30% to +30%
of the mean value, was used for the cost variables given
no distribution could be retrieved for these parameters,
and a binomial distribution was used for the transition
probability variables. Thereafter, 1000 cost and health
outcome estimates were computed by drawing a spe-
ciﬁc value from each distribution allowing the quanti-
ﬁcation of the uncertainty around the model outcomes
given the existing uncertainty around each input
parameter. The analysis was conducted using @risk
4.5® (Palisade, London, UK).
Results
Cumulative Incidence of ESRD and Number of
Cases Prevented
For all the health-care settings, the cumulative
incidence of ESRD, deﬁned as the proportion of the
patient population that develops ESRD over time, was
the lowest when the early irbesartan treatment strategy
was used, and it ranged between 9% in Malaysia and
14% in Taiwan. In comparison, the cumulative inci-
dence of ESRD when the late irbesartan treatment
strategy was used ranged between 18% in South Korea
and 25% in Taiwan. The incidence ranged between
22% in South Korea and 31% in Taiwan when the
standard therapy strategy was used. Finally, the model
indicated that the late amlodipine treatment strategy
yielded the highest cumulative incidence rates in all
settings (ranging between 24% in South Korea and
30% in Thailand) (see Fig. 2). The magnitude of
reduction in the cumulative ESRD incidence per 1000
patients was investigated. The model indicated that the
early irbesartan treatment strategy reduced the number
of ESRD incident cases for 1000 patient treated by 85
(South Korea) to 118 (Taiwan) when compared to the
late irbesartan treatment strategy, by 128 (South
Korea) to 177 (Taiwan) when compared to the stan-
dard treatment strategy, and by 144 (South Korea) to
198 (Taiwan) when compared to the late amlodipine
treatment strategy. Although the magnitude of reduc-
tion was comparable between countries, the maximal
reduction was reported in Taiwan, where the incidence
was the highest.
Number of Days in Dialysis
Across the settings, the number of days in dialysis per
patient was the lowest with the early irbesartan treat-
ment strategy, followed by the late irbesartan, stan-
dard, and late amlodipine treatment strategies in that
order. The number of days in dialysis was substantially
reduced when the early irbesartan treatment strategy
was used (the most dramatic reduction was reported inTa
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Taiwan, where the early irbesartan treatment strategy
yielded a reduction of 245.3 days per patient from the
number of days with the standard treatment strategy).
The reduction was fairly similar across all the health-
care settings—the early irbesartan treatment strategy
lowered the number of days in dialysis by 62%, 51%,
and 63% as compared to the standard, late irbesartan,
and late amlodipine treatment strategies, respectively.
Number of Years Free of ESRD
According to the model, the number of years free of
ESRD per patient (see Fig. 2) was the highest across
the health-care settings investigated when the early
irbesartan treatment strategy was used, ranging
between 10.5 years in South Korea and 12.4 years in
Taiwan. The number of years free of ESRD ranged
between 9.8 in South Korea and 11.5 in Taiwan
when the late irbesartan treatment strategy was used.
This value was still lower when the standard and late
amlodipine treatment strategies were used, with esti-
mates ranging between 9.6 and 11.2 years, and 9.5
and 11.1 years in South Korea and Taiwan, respec-
tively. Interestingly, when the early irbesartan treat-
ment strategy was used, the onset of ESRD was 1.5
and 1.8 years later in South Korea and Taiwan,
respectively, than that when the standard treatment
was used. This represents a 16% increase in the
ESRD-free duration.
Projected Effects on Life Expectancy
Finally, the life expectancy was the highest across all
settings investigated when the early irbesartan treat-
ment strategy was used; this was followed by the late
irbesartan, late amlodipine, and standard treatment
strategies in that order (see Fig. 2). The early irbe-
sartan treatment strategy yielded life expectancies
ranging between 10.8 years in South Korea and
12.8 years in Taiwan. When the early irbesartan treat-
ment strategy was used, the life expectancy was an
average of 4% to 6% higher than that reported for any
other treatment strategy.
Table 4 Annual transition probabilities used for each Asian setting
China
[32,33]
Malaysia
[34]
South
Korea*
Taiwan
[32,33,35]
Thailand
[36–38]
Transition from dls to tpt over year 1 0.062 0.001 0.024 0.009 0.010
Transition from dls to tpt over year 2 0.062 0.001 0.038 0.009 0.021
Transition from dls to tpt over year 3 0.062 0.003 0.022 0.009 0.004
Transition from dls to tpt over year 4 0.062 0.001 0.018 0.009 0.005
Transition from dls to tpt year 5 and after 0.062 0.003 0.031 0.009 0.008
Mortality from dls over year 1 0.102 0.140 0.107 0.149 0.090
Mortality from dls over year 2 0.102 0.151 0.119 0.124 0.099
Mortality from dls over year 3 0.102 0.178 0.069 0.111 0.110
Mortality from dls over year 4 0.102 0.167 0.071 0.101 0.123
Mortality from dls over year 5 and after 0.102 0.180 0.025 0.099 0.141
Mortality after tpt over year 1 0.042 0.070 0.017 0.021 0.028
Mortality after tpt over year 2 0.042 0.011 0.004 0.021 0.009
Mortality after tpt over year 3 0.042 0.033 0.007 0.021 0.009
Mortality after tpt over year 4 0.042 0.011 0.018 0.021 0.003
Mortality after tpt over year 5 and later 0.042 0.057 0.015 0.021 0.003
Transition from tpt to dls over year 1 0.015 0.000 0.017 0.015 0.096
Transition from tpt to dls over year 2 0.015 0.010 0.003 0.015 0.023
Transition from tpt to dls over year 3 0.050 0.010 0.005 0.050 0.024
Transition from tpt to dls over year 4 0.050 0.031 0.012 0.050 0.029
Transition from tpt to dls over year 5 and later 0.060 0.021 0.013 0.060 0.030
Immediate tpt upon ESRD 0.015 0.010 0.095 0.001 0.033
*Based on a chart review of 2311 ESRD patients newly identiﬁed at University Hospital Kidney Center during the periods of 1997–2002.
dls, dialysis; ESRD, end-stage renal disease; tpt, transplantation.
Table 5 Costs per year in each Asian setting ($)
China
[39–41]
Malaysia
[27]*
South
Korea†
Taiwan
[42,43]
Thailand
[37,38,44]
Cost of amlodipine 2,018 322 619 355 779
Cost of irbesartan 1,660 258 593 461 1,340
Cost of a dbt patient on dls 56,584 19,054 40,254 21,852 31,651
Cost of renal tpt of a dbt patient in the ﬁrst year 54,886 70,022 41,823 22,382 45,953
Cost (post index year) of a transplanted dbt patient 27,259 14,111 21,639 9,559 19,349
*Average costs in the private and NGO sectors and Malaysian medical association schedule of fees, 2002.
†Health Insurance Review Agency database and Pharmaceutical and Medical Care Beneﬁt Schedule of the National Health Insurance in Korea.
All costs are presented in terms of 2004 US$ values, taking into account purchase power parities.
dbt, diabetic; dls: dialysis; tpt, transplantation.
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Projected 25-Year Costs
The total costs per patient, expressed in terms of 2004
US$, differed greatly among the settings, with an
approximately fourfold difference between Malaysia
and China (see Fig. 3). Although the costs associated
with the early irbesartan treatment strategy were ini-
tially higher than those with other treatment strategies
(due to the higher cost of irbesartan), the model estab-
lished that the early irbesartan treatment strategy was
eventually cost-saving—after 11 years in Malaysia,
Taiwan, 13 years in South Korea, 16 years in China,
and 20 years in Thailand. At the end of the time
horizon of the model (25 years), the early irbesartan
treatment strategy was consistently found to be the
least expensive across the health-care settings, with
costs of $8,455 in Malaysia, $12,961 in South Korea,
$29,737 in Thailand, $25,790 in Taiwan, and $42,990
in China. The costs for the late irbesartan, standard,
and late amlodipine treatment strategies were, respec-
tively, $2,980 to $13,484, $6,189 to $21,148, and
$8,200 to $29,732 higher than that of early irbesartan
treatment.
Sensitivity Analysis
One-way deterministic sensitivity analysis was con-
ducted to evaluate the effect of uncertainty in key
parameters on the results. When the annual probabil-
ity of death in the early stages (i.e., during MAU,
early diabetic nephropathy, and advanced diabetic
nephropathy) varied between -50% and +50% of the
values in the base-case analysis, results remain in
favor of early irbesartan in all settings. More speciﬁ-
cally, both increasing MAU mortality and decreasing
diabetic nephropathy mortality reduced the beneﬁcial
effect of early irbesartan treatment in terms of
decreased life-years gained compared to the base case.
Nevertheless, the early irbesartan treatment strategy
remained dominant over the other treatment alterna-
tives. The sensitivity analyses also indicated that the
results were not impacted by changes in the trans-
plantation probability.
Finally, the model’s cost results appeared to be sen-
sitive to changes in the cost of irbesartan. When the
irbesartan cost increased by 50%, irbesartan remains
dominant in all settings except in Thailand. Similar
results were obtained by reducing the costs of dialysis
by 50%. In all the other settings the dominance of
irbesartan is maintained with extreme input data.
In addition, the second-order Monte Carlo sensitiv-
ity analysis established that the early irbesartan treat-
ment strategy presented a higher probability of
dominance (higher clinical beneﬁts and lower costs)
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Figure 2 Summarized results of models operated in a 25-year time frame and 3% discount rate for both costs and outcomes. Mean and 95% conﬁdence
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than the standard treatment strategy. The 1000 cost
and health outcome estimates computed by drawing a
speciﬁc value for each parameter’s distribution showed
life-year gained and cost savings for irbesartan com-
pared to standard treatment strategy in at least 66% of
the cases in Thailand and up to 95.3% of the cases in
Taiwan. Compared to the other treatment strategies,
the early irbesartan treatment strategy had a 78% and
93% probability of dominance in Thailand over the
late irbesartan and the late amlodipine treatment strat-
egies, respectively. The 1000 second-order Monte
Carlo estimates computed when the early irbesartan
treatment strategy was used compared to when the
standard treatment strategy was used are graphically
presented for all Asian settings in the cost-effectiveness
planes (Fig. 4).
Discussion
This analysis aimed at adapting a Markov model that
was previously developed for Western countries to dif-
ferent Asian health-care settings (China, Thailand,
Taiwan, South Korea, and Malaysia). In all ﬁve set-
tings, the model indicated that treating patients by
standard hypertension treatment plus 300 mg/day
irbesartan administered at the onset of MAU could
result in cost savings as early as 11 years after the onset
of MAU in some Asian settings such as Malaysia or
Taiwan. More importantly, this treatment strategy was
associated with longer life expectancy and a shorter
duration of dialysis as compared to the other treatment
options (61% to 63% shorter duration of dialysis
compared to the standard hypertensive treatment
strategy). Furthermore, the sensitivity analysis estab-
lished the probability that early irbesartan treatment
would predominate over the standard treatment, and it
ranged between 66% in Thailand (where the beneﬁcial
effect was the lowest) and 95% in Taiwan (where the
beneﬁcial effect was the highest).
Some limitations of this study have been identiﬁed.
The model excluded the costs of comedication for
diseases other than diabetic nephropathies. In light of
the impact of combination therapies used for hyper-
tension control and their associated costs, this exclu-
sion might, however, be considered conservative. In
fact, a higher degree of blood pressure control may be
achieved by these treatment strategies, thus reducing
the need for additional treatment for comorbidities
other than diabetic nephropathies [15]. Further,
comparison between the different settings could be
reviewed in light of the differences in data sources used
to operate the model but also lack of Asian-speciﬁc
data for some of the transition probabilities. Critical
analysis of the input data, however, revealed that there
were no major differences among input data obtained
from literature, databases, or expert opinion; this
underlined the relevance of the comparisons per-
formed in this study.
Finally, this model uses a unique disease pattern
across the settings, which may undermine the local
differences in the clinical management of these patients
among the different settings. Nevertheless, it is well
accepted that economic evaluations simplify disease
progression to cover most cases in a given setting.
Furthermore, for patients with ESRD, dialysis and
transplantation are the main treatment alternatives,
and both these alternatives were considered by the
model in a country-speciﬁc manner. Moreover, the
CHINA
$0
$20,000
$40,000
$60,000
$80,000
0 yr 10 yr 20 yr 30 yr
eralIRB
lateIRB
AML
STD
TAIWAIN
$0
$20,000
$40,000
$60,000
$80,000
0 yr 10 yr 20 yr 30 yr
MALAYSIA
$0
$20,000
$40,000
$60,000
$80,000
0 yr 10 yr 20 yr 30 yr
THAILAND
$0
$20,000
$40,000
$60,000
$80,000
0 yr 10 yr 20 yr 30 yr
SOUTH KOREA
$0
$20,000
$40,000
$60,000
$80,000
0 yr 10 yr 20 yr 30 yr
Figure 3 Cumulative total costs over time in
US$ per region.AML, amlodipine; earlIRB, early
irbesartan; lateIRB, late irbesartan; STD, stan-
dard therapy.
Cost-Effectiveness of Irbesartan in Asia 361
model structure was further validated in each speciﬁc
setting by local experts.
With regard to the results, the gain in life expect-
ancy for the ﬁve settings investigated with early irbe-
sartan ranged between 0.31 and 0.48 life-years over
the standard treatment strategy, between 0.33 and
0.44 life-years over the late irbesartan strategy, and
between 0.30 and 0.49 life-years over the late amlo-
dipine treatment strategy. These results are in the same
range as those obtained in other adaptations of this
model. For instance, the US version of this analysis
yielded a gain of 0.96 discounted life-years over the
standard treatment and 0.92 life-years over the late
irbesartan treatment strategies [14], while the Belgian
and French models yielded life-year gains ranging
between 0.62 and 0.61 years over the standard treat-
ment and between 0.46 and 0.45 years over the amlo-
dipine treatment strategies [14].
Such comparable results can be explained by the
method used in the seminal model to adapt to the
different settings. The transition probabilities between
the different health stages originate from the same
clinical trials, except for themortality-related transition
probabilities that were obtained from local sources for
each adaptation. Therefore, the impact of modifying
mortality-related transition probabilities was included
in the sensitivity analysis. Although increasing MAU
mortality or reducing overt nephropathy mortality did
reduce the reported difference in life expectancy with
regard to the base-case scenario for the early irbesartan
treatment strategy, varying the mortality-related prob-
abilities did not impact the model’s conclusion.
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Figure 4 Cost-effectiveness plane (difference in incremental costs vs. difference in incremental life expectancy [LY]) with Monte Carlo simulation for each
Asian setting comparing early irbesartan treatment to the standard treatment (*base-case value).
362 Annemans et al.
Contrary to the reported outcomes, the economic
results of the model are extremely different from those
reported in Europe and the United States, with differ-
ences being up to 11 times higher in the United States
[14] than in Malaysia.
To further investigate the cause of such variations,
the results of this adaptation were compared to the
gross domestic products (GDPs) of the countries
involved in this analysis expressed in 2004 US$. These
ﬁve settings presented very different characteristics in
terms of the GDP per capita ($5600 in China, $8100
Thailand, $9700 in Malaysia, $19,200 in South Korea,
and $25,300 in Taiwan).
Overall, the differences in the results observed
between the different Asian settings correlate well with
the GDPs, with Malaysia showing the lowest costs and
among the lowest GDP and Taiwan the highest costs
and GDP. In this crude comparison, China appeared to
be an outlier, perhaps because of the fact that the costs
used in this analysis were mainly from urban regions,
whereas GDP of China ($5600 per capita) reﬂects the
costs in both rural and urban settings.
Interestingly, previous analysis of health economic
evaluations for many countries, although focusing on
Western countries, already highlighted that resource
use and therefore cost data were the main drivers of
between-country variation [31]. Therefore, the current
analysis and previous studies highlight the relevance of
adapting international models to local settings since
the transferability of economic analyses from one
setting to another is challenged by disease management
and access to health care.
The conclusion of the current adaptation did not
differ from the previous European or US versions of
the model for the ﬁve Asian settings analyzed. Early
irbesartan treatment was indeed a better alternative to
standard, late irbesartan, or late amlodipine treat-
ments. Nevertheless, it is evident that the results of
health economic analyses cannot be generalized for
different countries since the variations in results are
not systematic [31].
In conclusion, this Asian adaptation of a peer-
reviewed health economic model conﬁrmed the advan-
tage of initiating irbesartan therapy in hypertensive
type 2 diabetics as early as the MAU stage. This treat-
ment strategy increased life expectancy, reduced the
occurrence of ESRD and the resulting need for dialysis,
and thereafter reduced the overall cost in the ﬁve Asian
settings investigated.
Source of ﬁnancial support: This study was funded by an
unrestricted grant from Sanoﬁ-Aventis.
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